|
Study to assess immunogenicity, reactogenicity and safety of a 2nd dose of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine given in healthy children of 5 to 6 years of age |
Combined Measles, Mumps, Rubella, Varicella Vaccine |
208136/017 (MeMuRu-OKA-017) |
|
Measles; Mumps; Rubella; Varicella |
Phase 2 |
|
|
|
|
An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. |
September 2015 |